Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The drug Egrifta (tesamorelin), developed as a treatment for excess abdominal fat in people with HIV, may have an additional benefit of promot...
The injectable drug Egrifta (tesamorelin) led to modest drops in abdominal and liver fat levels in a preliminary study of people with HIV.
Theratechnologies has announced a major shortage of its drug Egrifta (tesamorelin, for injection), which reduces HIV-related excess belly fat.
While newer antiretrovirals have reduced the prevalence of lipodystrophy, a significant proportion of the HIV population still suffers from th...
Egrifta (tesamorelin), a drug approved to reduce gut fat accumulation, also reduces cellular inflammation.
Egrifta (tesamorelin), the lipodystrophy treatment approved by the U.S. Food and Drug Administration (FDA) late last year, is now officially a...
The first of a two-part look at the top treatment news of 2010.
Egrifta (tesamorelin) has been approved for the treatment of HIV-associated lipodystrophy, according to a November 10 announcement from...
FDA advisory panel is convening this week to decide whether to recommend approval of Egrifta, a belly fat-busting drug.
A U.S. Food and Drug Administration independent advisory committee is set to review Montreal-based Theratechnologies’ New Drug Application..
Montreal-based Theratechnologies announced yesterday that the U.S. Food and Drug Administration (FDA) will reschedule its meeting with...
In honor of World AIDS Day, AIDSmeds highlights the year’s top treatment stories.
Two experimental therapies may ease a big HIV-related bellyache: excess deep belly fat or visceral adipose tissue (VAT).
If approved, tesamorelin will be sold in the United States by EMD Serono.
A new non-nuke, the apparent cure of an HIV-positive patient receiving a bone marrow transplant and the possibility of earlier...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.